The European Medicines Agency (EMA) has approved Merial's, an  animal health division of Sanofi, Broadline, a unique product in the fight against external parasites offering additional internal parasite control for cats and kittens.

Broadline is a topical product approved for the treatment and prevention of flea and tick infestations, prevention of  heartworm  disease, and the treatment of roundworm, hookworm, and tapeworm infestations in cats and kittens seven weeks of age and older. Broadline is a combination of four active ingredients and helps protect cats for one month.

“Broadline leverages Merial’s years of experience and technical parasiticide knowledge into  this novel and innovative product”, said Carsten Hellmann, CEO of Merial. “Merial is a market leader for pets parasiticide products and we are pleased to provide veterinarians with an all-in-one feline parasiticide that offers broad spectrum protection and is administered topically, which cat owners typically prefer.”

This innovative parasite treatment and prevention product was developed by Merial R&D centres in Europe and in the United States. Broadline has been proven safe and effective in extensive laboratory and clinical studies. The European Commission granted the marketing authorization valid throughout the European Union. Broadline will be a prescription-only product and is expected to be available in time for the next flea and tick season.

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals.

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.